Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
December 17, 2024 08:50 ET
|
Sonnet BioTherapeutics Holdings, Inc.
Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) Executed licensing agreement to support initiation of a Phase 2...